{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:14:17Z","timestamp":1792721657936,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009396","name":"Universit\u00e4tsspital Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.modpat.2024.100683","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T22:19:01Z","timestamp":1734128341000},"page":"100683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Frequency and Consequences of Immune Checkpoint Inhibitor\u2013Associated Inflammatory Changes in Different Organs: An Autopsy Study Over 13 -Years"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3253-3787","authenticated-orcid":false,"given":"Umberto","family":"Maccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Wolleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Moch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.modpat.2024.100683_bib1","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.modpat.2024.100683_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1200\/JCO.20.03420","article-title":"Clinical cancer advances 2021: ASCO's report on progress against cancer","volume":"39","author":"Smith","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.modpat.2024.100683_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events","volume":"19","author":"Jing","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.modpat.2024.100683_bib6","doi-asserted-by":"crossref","first-page":"vii17","DOI":"10.1093\/rheumatology\/kez465","article-title":"Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors","volume":"58","author":"Ibraheim","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.modpat.2024.100683_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2024.100683_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"10.1016\/j.modpat.2024.100683_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.modpat.2024.100683_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1410928","article-title":"The role of the gut microbiota in tumor, immunity, and immunotherapy","volume":"15","author":"Xie","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.modpat.2024.100683_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune checkpoint inhibitor-associated colitis: from mechanism to management","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2024.100683_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib14","first-page":"123","article-title":"Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist","volume":"93","author":"Tattersall","year":"2020","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.modpat.2024.100683_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.modpat.2024.100683_bib17","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.modpat.2024.100683_bib18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.modpat.2024.100683_bib19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.modpat.2024.100683_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.modpat.2024.100683_bib21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases","volume":"13","author":"Zotova","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"10.1016\/j.modpat.2024.100683_bib22","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/PAS.0000000000001298","article-title":"Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis","volume":"43","author":"Larsen","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.modpat.2024.100683_bib23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/his.14704","article-title":"Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease","volume":"81","author":"Imran","year":"2022","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.modpat.2024.100683_bib25","first-page":"3751","article-title":"Histological characteristics and management of hepatitis on immune checkpoint inhibitors: a retrospective descriptive study","volume":"12","author":"Parlati","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.modpat.2024.100683_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.modpat.2024.100683_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.modpat.2024.100683_bib29","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s00262-021-02983-8","article-title":"Immune checkpoint inhibitors-induced nephropathy: a French national survey","volume":"70","author":"G\u00e9rard","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.modpat.2024.100683_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11894-023-00885-6","article-title":"Immune checkpoint inhibitor-induced (type 3) autoimmune pancreatitis","volume":"25","author":"Shirwaikar Thomas","year":"2023","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"10.1016\/j.modpat.2024.100683_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eprac.2020.09.016","article-title":"Immune checkpoint inhibitor-induced adrenalitis and primary adrenal insufficiency: systematic review and optimal management","volume":"27","author":"Shi","year":"2021","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.modpat.2024.100683_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.modpat.2024.100683_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.modpat.2024.100683_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2024.100683_bib35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.modpat.2024.100683_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41199-020-0050-3","article-title":"Pembrolizumab-induced hemophagocytic lymphohistiocytosis: an immunotherapeutic challenge","volume":"5","author":"Kalmuk","year":"2020","journal-title":"Cancers Head Neck"},{"issue":"2","key":"10.1016\/j.modpat.2024.100683_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14740\/wjon1464","article-title":"Hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitor therapy","volume":"13","author":"Rajapakse","year":"2022","journal-title":"World J Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2024.100683_bib38","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.modpat.2024.100683_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/TCRM.S191022","article-title":"Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Jiang","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"10.1016\/j.modpat.2024.100683_bib40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"10.1016\/j.modpat.2024.100683_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310919","article-title":"Pembrolizumab-induced fatal myasthenia, myocarditis, and myositis in a patient with metastatic melanoma: autopsy, histological, and immunohistochemical findings-a case report and literature review","volume":"24","author":"Giovannini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.modpat.2024.100683_bib42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.modpat.2024.100683_bib43","article-title":"An autopsy case of immune-related severe colitis due to long-term use of nivolumab in a patient with non-small cell lung cancer","volume":"39","author":"Fujikawa","year":"2022","journal-title":"Respir Med Case Rep"},{"issue":"5","key":"10.1016\/j.modpat.2024.100683_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.152009","article-title":"The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events","volume":"225","author":"Mihic-Probst","year":"2020","journal-title":"Immunobiology"},{"key":"10.1016\/j.modpat.2024.100683_bib45","first-page":"17","article-title":"Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis","volume":"15","author":"Shea","year":"2018","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"10.1016\/j.modpat.2024.100683_bib46","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00103-020-03221-9","article-title":"[Checkpoint inhibitors for cancer therapy]","volume":"63","author":"Zander","year":"2020","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib47","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.modpat.2024.100683_bib48","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.modpat.2024.100683_bib49","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.modpat.2024.100683_bib50","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"issue":"10124","key":"10.1016\/j.modpat.2024.100683_bib51","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.modpat.2024.100683_bib52","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.modpat.2024.100683_bib53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"issue":"11","key":"10.1016\/j.modpat.2024.100683_bib54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"10.1016\/j.modpat.2024.100683_bib55","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/cancers15092561","article-title":"Granulomatous and sarcoid-like immune-related adverse events following CTLA4 and PD1 blockade adjuvant therapy of melanoma: a combined analysis of ECOG-ACRIN E1609 and SWOG S1404 phase III trials and a literature review","volume":"15","author":"Eljilany","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.modpat.2024.100683_bib56","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/cancers14122937","article-title":"Sarcoid-like granulomatosis associated with immune checkpoint inhibitors in melanoma","volume":"14","author":"Melin","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14618","article-title":"Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case","volume":"34","author":"Apalla","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.modpat.2024.100683_bib58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2021.07.015","article-title":"Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: a case-control study","volume":"156","author":"Cabani\u00e9","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.modpat.2024.100683_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1156474","article-title":"Cardiac sarcoidosis: a comprehensive review of risk factors, pathogenesis, diagnosis, clinical manifestations, and treatment strategies","volume":"10","author":"Shah","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.modpat.2024.100683_bib60","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5858\/2009-0274-RA.1","article-title":"Cardiac sarcoidosis: a pathology-focused review","volume":"134","author":"Lagana","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10.1016\/j.modpat.2024.100683_bib61","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.006145","article-title":"Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block","volume":"11","author":"Nordenswan","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2","key":"10.1016\/j.modpat.2024.100683_bib62","article-title":"Lymph vessel proliferation on cardiac biopsy may help in the diagnosis of cardiac sarcoidosis","volume":"8","author":"Oe","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.modpat.2024.100683_bib63","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.modpat.2024.100683_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102452","article-title":"Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias","volume":"110","author":"Kfoury","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.modpat.2024.100683_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.modpat.2024.100683_bib66","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221130576","article-title":"A\u00a0retrospective cohort study of multiple immune-related adverse events and clinical outcomes among patients with cancer receiving immune checkpoint inhibitors","volume":"29","author":"Hata","year":"2022","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.modpat.2024.100683_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265230","article-title":"Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms","volume":"17","author":"Osawa","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib68","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2019-0083","article-title":"Diagnosis and management of rare immune-related adverse events","volume":"25","author":"Schoenfeld","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.modpat.2024.100683_bib69","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1093\/oncolo\/oyac056","article-title":"Incidence, clinical characteristics, and predictors of cardiovascular immune-related adverse events associated with immune checkpoint inhibitors","volume":"27","author":"Isawa","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.modpat.2024.100683_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1091185","article-title":"Frequency and clinical characteristics of hypophysitis and hypopituitarism in patients undergoing immunotherapy - a systematic review","volume":"14","author":"Jacques","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.modpat.2024.100683_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"4","key":"10.1016\/j.modpat.2024.100683_bib72","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.modpat.2024.100683_bib73","first-page":"7563","article-title":"Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience","volume":"29","author":"Taliansky","year":"2021","journal-title":"Support Care Cancer"},{"issue":"9935","key":"10.1016\/j.modpat.2024.100683_bib74","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.modpat.2024.100683_bib75","article-title":"Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis","volume":"12","author":"Bando","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.modpat.2024.100683_bib76","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.3390\/curroncol29070370","article-title":"Routine screening for central and primary adrenal insufficiency during immune-checkpoint inhibitor therapy: an endocrinology perspective for oncologists","volume":"29","author":"Druce","year":"2022","journal-title":"Curr Oncol"},{"issue":"28","key":"10.1016\/j.modpat.2024.100683_bib77","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2024.100683_bib78","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/apt.13281","article-title":"Systematic review: colitis associated with anti-CTLA-4 therapy","volume":"42","author":"Gupta","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.modpat.2024.100683_bib79","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.modpat.2024.100683_bib80","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100683_bib81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-017-2267-z","article-title":"Immune checkpoint inhibitor colitis: the flip side of the wonder drugs","volume":"472","author":"Assarzadegan","year":"2018","journal-title":"Virchows Arch"},{"issue":"17","key":"10.1016\/j.modpat.2024.100683_bib82","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM198304283081704","article-title":"The value of the autopsy in three medical eras","volume":"308","author":"Goldman","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.modpat.2024.100683_bib83","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/modpathol.2011.199","article-title":"Diagnostic errors in the new millennium: a follow-up autopsy study","volume":"25","author":"Schwanda-Burger","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2024.100683_bib84","article-title":"Clinically undiagnosed diseases in autopsies: frequency and risk factors","author":"Maccio","year":"2024","journal-title":"Arch Pathol Lab Med"},{"issue":"36","key":"10.1016\/j.modpat.2024.100683_bib85","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224002631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224002631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:14:18Z","timestamp":1753485258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395224002631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0893395224002631"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100683","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency and Consequences of Immune Checkpoint Inhibitor\u2013Associated Inflammatory Changes in Different Organs: An Autopsy Study Over 13 -Years","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100683"}}